Somite AI, which is developing AI foundation models for stem cell therapies, raised a $47M+ Series A led by Khosla Ventures, taking its total funding to ~$60M
Gil Press / Forbes :
Context & Ripple Effects
Somite enters an AI-biology funding arc that includes Immunai's earlier $60M Series A for AI-driven immune-system analysis and Bioptimus's $41M round to build a foundational biology model. The common thread is venture backing for software models aimed at biological data and workflows rather than a single drug program.
Khosla Ventures' lead role also connects Somite to a broader investor push into AI-native companies, while the company’s roughly $60M cumulative financing gives it a more substantial base than a seed-stage experiment.
First-order effects
- Somite gains more than $47M in new capital and a lead investor, lifting its disclosed funding to roughly $60M as it develops foundation models for stem-cell therapies.
- Khosla Ventures deepens its exposure to AI applied to biological research and therapeutic development through a company positioned at the stem-cell layer.
Second-order effects
- The round raises the competitive bar for other AI-biology developers, including companies building broad biology models or AI-enabled drug-development platforms, to show that their model approach can attract comparable specialist capital.
- Investors and prospective partners can more clearly treat stem-cell-focused models as part of the wider AI-biology category, alongside Formation Bio's AI drug co-development platform rather than as an isolated research tool.
Third-order effects
- If funding continues to cluster around model-centric biology companies, the sector may increasingly organize around a small set of well-capitalized platforms that can finance data, model development, and validation over long timelines.
- That would make investor concentration a meaningful determinant of which AI-biology approaches reach downstream therapeutic development, though this single financing does not establish that outcome.
The trend: AI-biology investment is broadening from analytics and drug-development software toward foundation-model companies targeting distinct biological domains.